Unparalleled Psychedelic Investing Data and Analysis

Psychedelic Invest is a resource for those looking to invest in the burgeoning psychedelic industry.

Track the entire psychedelic market

Track the entire psychedelic market

We’ve developed the first all encompassing index to track the public psychedelic marketplace.

Explore the Index

Just Some of the Data we Cover

Latest News

Press

Psyence Group Launches its Functional Mushroom Brand, “Goodmind”

Psyence Group Inc. announced it has launched its functional mushroom brand, “GOODMIND”

Cybin Press

Cybin Inc. Announces Uplisting to OTCQB Venture Market

Cybin Inc. today announced its successful uplisting from the OTC Pink Sheets to the OTCQB® Venture Market.

Atai Life Sciences Press

atai Life Sciences Announces the Closing of its $157 Million Series D Financing Round

Quick Take The Series D fundraising saw participation from existing and new investors including Fearless Ventures, Falcon Edge Capital, Pura Vida Pro LLC, Catalio Capital Management, Michael Auerbach’s Subversive Capital, Highline Capital, and Woodline Partners Proceeds from this financing round will support the expansion and development of the atai’s drug candidate pipeline, enabling technologies, and […]

noetic fund Interview

Investing in Psychedelic Medicine and Sustainable Solutions for Mental Health and Well Being

To learn more about what the fund is building and where it sees the future going in the psychedelic space, we sat down with Noetic’s three managing partners: Michael Franks, Sa’ad Shah and Naseem Saloojee.

TheraPsil Press

TheraPsil Launches Beta Version of Psilocybin Therapy Training Program

TheraPsil announced the launch of its Health-Canada-approved, phase 1 psilocybin therapy training program for healthcare professionals.

MindMed Press

MindMed Closes Acquisition of HealthMode, a Leading Machine Learning Digital Medicine Company

Mind Medicine (MindMed) Inc. announced that it has closed the previously announced acquisition of HealthMode.

Psybio Therapeutics Press

PsyBio Therapeutics Corp. Begins Trading on the TSX Venture Exchange

PsyBio Therapeutics Corp. announced that the company will commence trading on the TSX Venture Exchange under the ticker symbol “PSYB”.

Explore the Psychedelic Landscape

Learn more about the psychedelic companies changing the industry.